Bone status of children aged 5–8 years, treated with dexamethasone for chronic lung disease of prematurity
- J A Eelloo1,2,3,
- S A Roberts1,2,3,
- A J B Emmerson1,2,3,
- K A Ward1,2,3,
- J E Adams1,2,3,
- M Z Mughal1,2,3
- 1Department of Neonatology and Paediatrics, St Mary’s Hospital for Women and Children, Central Manchester and Manchester Children’s Hospitals NHS Trust, Manchester, UK
- 2Biostatistics Group, School of Epidemiology and Health Sciences, University of Manchester, Manchester, UK
- 3Clinical Radiology, Imaging Science and Biomedical Engineering, University of Manchester, Manchester, UK
- Dr M Z Mughal, Department of Paediatric Medicine, St Mary’s Hospital for Women and Children, Hathersage Road, Manchester M13 0JH, UK; zulf.mughal{at}cmmc.nhs.uk
- Accepted 5 August 2007
- Published Online First 17 August 2007
Abstract
Background: It is not known whether treatment with dexamethasone in the neonatal period may lead to reduced bone mineral density in childhood.
Methods: Anthropometric and bone densitometry measurements were taken of children aged 5–8 years who had chronic lung disease (CLD) in the neonatal period (n = 22). 15 of these children were treated with dexamethasone. A control group consisted of children born preterm who did not develop CLD (n = 29).
Results: Total body bone mineral content and bone mineral apparent density of the lumbar spine were lower in children whose CLD was treated with dexamethasone in the neonatal period, compared with the preterm controls.
Conclusion: Dexamethasone treatment in the neonatal period appears to cause impairment of mineralisation which persists into childhood.
Footnotes
-
Funding:The study was funded by St Mary’s Hospital Neonatal Medical Unit Research Endowment fund.
-
Competing interests: None.
-
Ethical approval: The Central Manchester Local Research Ethics Committee study approved the study.
